Spending power
TheGrid Corporate Spending Power index would rate purchasing capacity from registry, scale and activity signals.
Spending power
Key facts
Counted staff
16
self-reported 11–50 band
Founded
1986
40 years
Legal entities
1
ABR
Office countries
1
1 address
Funding rounds
None on record
Company type
Public Company
self-reported
Legal entity
1 brand → 1 confirmed entity
Cyclopharm Limited
ABN74116931250
Legal entities
Show as table · Cyclopharm: 1 registry entity
| Cyclopharm Limited | ABN 74116931250 |
|---|---|
| Confirmed matches | 0 of 1 |
A candidate is a name match on the registry, not a confirmed identity, and two candidates are ambiguity rather than a corporate structure.
Description
Cyclopharm is an Australian ASX listed medical device company primarily involved in the field of nuclear medicine.
Technegas, Cyclopharm’s foundation product is a lung ventilation imaging agent, is a structured ultra-fine dispersion of radioactive labeled carbon. Technegas is produced by drying Technetium-99m, (the most commonly used isotope in nuclear medicine imaging), in a carbon crucible then heating the isotope for a few seconds at around 2,700oC in a Technegas Generator. The resultant gas-like substance is inhaled by the patient (referred to as lung ventilation) via our consumable product known as a Patient Administration Set (PAS).
The inhaled Technegas particles enables multiple views and tomography imaging under a gamma or single photon emission computed tomography (SPECT) camera for superior functional ventilation imaging. Technegas is best known for its use in diagnosing Pulmonary Embolism (PE); however, Technegas is now being investigated for additional indications to include the diagnosis and management of COPD, Asthma, CTEPH and the effectiveness of lung reduction interventions Ultralute, a new product developed by Cyclopharm will be released to the market later in 2016. This first in class, proprietary technology is designed to improve the efficiency, productivity and health care economics in the production of radiopharmaceuticals.
Specialties
All 4 specialties
- Nuclear Medicine
- Diagnostic Imaging
- Medical Devices
- Respiratory Medicine
Locations
Country footprint
Show as table · Offices in 1 country
| Countries | 1 |
|---|---|
| Primary country | AU |
All codes: AU
Addresses
- AU1 The Crescent; Unit 1; Kingsgrove, NSW 2208Primary
Grid intelligence Members
Signals & hiring
Hiring, headcount and registry-change signals, streamed to members.
Latest signal
Hiring activity
Headcount trend
Financials
Registry-filed capital and financial indicators, standardised by TheGrid.
Paid-up capital
Fiscal period
Registered charges
Revenue
Profit / loss
People & contacts
4 employee profiles on record · names withheld.
Names and titles are intentionally absent from this page. The source relation carries no consent record across the privacy regimes this directory spans, so it is never requested and never stored. Search engines see exactly what you see here.
The people relation is never requested, so there is nothing here to unlock.
FAQ
Which legal entity operates under Cyclopharm?
One New South Wales entity on the ABR: Cyclopharm Limited (ABN 74 116 931 250), high confidence.
How many people work at Cyclopharm?
16 counted staff profiles at January 2026, inside the self-reported 11–50 band.
Where does Cyclopharm have offices?
One address on record, Australia only. Primary: 1 The Crescent, Unit 1, Kingsgrove, NSW 2208.
Has Cyclopharm raised funding?
None linked to this brand.
What does Cyclopharm list as its specialties?
Four tags on the brand's own list, among them nuclear medicine, diagnostic imaging and medical devices.
Which companies are listed alongside Cyclopharm?
5 profiles list Cyclopharm as a peer — 74th percentile in Medical Device. It lists ten peers of its own. Maxx Pharma Pty Ltd and Cyclomedica list it back.